Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial

DOI Full Paper Access

52

Citations

16

References

2020

Year

Mala Dharmalingam, S. R. Aravind, Hemant Thacker, Brij Mohan, Manoj Chawla, Arthur Asirvatham, Ramesh K. Goyal, Jayashri Shembalkar, Pradnya Kadam, Hansraj Alva,

Abstract

CTRI/2017/07/009121.

References

	Year	Citations

Page 1